Literature DB >> 12111907

Early selection in a randomized phase II clinical trial.

Seth M Steinberg1, David J Venzon.   

Abstract

A randomized phase II clinical trial design can be employed when one wishes to be able to select one of several similar therapies or variants of a therapy for inclusion in a subsequent, definitive, phase III trial. It is not necessary in this type of trial to formally identify a superior arm using the usual parameters and stringent criteria employed for hypothesis testing. Simon, Wittes and Ellenberg have described methods and sample sizes for selecting the superior arm from among k possible arms. In this paper, we describe an approach based on statistical selection theory which allows one to potentially make a decision to end accrual to a randomized phase II trial at an interim point of the trial, and to select one of two arms as being worthy of further evaluation in a subsequent study. This method requires that an adequate gap in the number of responses between the two arms be observed at the interim point in order to limit the probability that the selected arm is actually inferior by more than an indifference amount. Published in 2002 by John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2002        PMID: 12111907     DOI: 10.1002/sim.1150

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

Review 1.  Statistics in clinical trials.

Authors:  Stephanie J Green; Donna K Pauler
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

2.  Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.

Authors:  Ying Huang; Peter B Gilbert; Rong Fu; Holly Janes
Journal:  Biostatistics       Date:  2017-04-01       Impact factor: 5.899

3.  Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.

Authors:  Rajen Mody; Alice L Yu; Arlene Naranjo; Fan F Zhang; Wendy B London; Barry L Shulkin; Marguerite T Parisi; Sabah-E-Noor Servaes; Mitchell B Diccianni; Jacquelyn A Hank; Mildred Felder; Jennifer Birstler; Paul M Sondel; Shahab Asgharzadeh; Julia Glade-Bender; Howard Katzenstein; John M Maris; Julie R Park; Rochelle Bagatell
Journal:  J Clin Oncol       Date:  2020-04-28       Impact factor: 44.544

4.  NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Authors:  Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker
Journal:  J Natl Cancer Inst       Date:  2012-12-10       Impact factor: 13.506

5.  Randomized phase II trials: time for a new era in clinical trial design.

Authors:  Sumithra J Mandrekar; Daniel J Sargent
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

6.  Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

Authors:  Rajen Mody; Arlene Naranjo; Collin Van Ryn; Alice L Yu; Wendy B London; Barry L Shulkin; Marguerite T Parisi; Sabah-E-Noor Servaes; Mitchell B Diccianni; Paul M Sondel; Julia G Bender; John M Maris; Julie R Park; Rochelle Bagatell
Journal:  Lancet Oncol       Date:  2017-05-23       Impact factor: 41.316

7.  Between-arm comparisons in randomized Phase II trials.

Authors:  Sin-Ho Jung; Stephen L George
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

8.  Proper inference from Simon's two-stage designs.

Authors:  Tatsuki Koyama; Heidi Chen
Journal:  Stat Med       Date:  2008-07-20       Impact factor: 2.373

9.  Randomized phase II clinical trials.

Authors:  Sin-Ho Jung; Daniel J Sargent
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

10.  Consumption of Sutherlandia frutescens by HIV-Seropositive South African Adults: An Adaptive Double-Blind Randomized Placebo Controlled Trial.

Authors:  Douglas Wilson; Kathy Goggin; Karen Williams; Mary M Gerkovich; Nceba Gqaleni; James Syce; Patricia Bartman; Quinton Johnson; William R Folk
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.